---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-114286"
form_type: "8-K"
ticker: null
cik: "0001017491"
company_name: "SEELOS THERAPEUTICS, INC."
filed_at: "2023-11-03T23:59:59+00:00"
generated_at: "2026-06-08T21:49:51.086744+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Seelos receives Nasdaq notices for bid price and market value non-compliance

## Summary
- Bid price below $1.00 for 30 consecutive days; compliance deadline April 29, 2024.
- Market value of listed securities below $35M for 32 consecutive days; deadline April 30, 2024.
- Company may effect a reverse stock split to cure deficiencies; no immediate trading impact.
- Failure to comply may lead to delisting; company may appeal Nasdaq's determination.
- Stock continues trading on Nasdaq Capital Market under symbol SEEL.

## SEC filing metadata
- accession: 0001104659-23-114286
- form_type: 8-K
- cik: 0001017491
- company_name: SEELOS THERAPEUTICS, INC.
- filed_at: 2023-11-03T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1017491/000110465923114286/0001104659-23-114286-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1017491/000110465923114286/tm2329801d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-114286
- JSON: https://secwatch.observer/filing/0001104659-23-114286.json
- Plain text: https://secwatch.observer/filing/0001104659-23-114286.txt

## Key facts
- Listing & Compliance Notices
  SEELOS THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: market value
  - Rules: 5550(b)(2)
  source text: ith the First Notice, the “Notices”) from Nasdaq indicating that, for the last thirty-two consecutive business days, the market value of the Company’s listed securities has been below the minimum requirement of $35 million for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2) (“Rule 5550(b)(2)”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided a period of 180 calendar days, or until April 30, 2024, to regain compliance. The Second Notice states that the Nasdaq staff will provide written notification that the Company has achi
  evidence_url: https://www.sec.gov/Archives/edgar/data/1017491/000110465923114286/0001104659-23-114286-index.htm
- Listing & Compliance Notices
  SEELOS THERAPEUTICS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: November 1, 2023, Seelos Therapeutics, Inc. (the “Company”) received written notice (the “First Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until April 29, 2024, to regain compliance. The F
  evidence_url: https://www.sec.gov/Archives/edgar/data/1017491/000110465923114286/0001104659-23-114286-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.